Galimov Sh N, Akhmetov R M, Galimova E F, Bairamgulov F M, Bikkulova L R
Bashkir State Medical University of Minzdrav of Russia, Ufa, Russia.
Republican Perinatal Center, Ufa, Russia.
Urologiia. 2017 Jun(2):88-92. doi: 10.18565/urol.2017.2.88-92.
To characterize the effect of the Speroton complex on the free radical homeostasis in the ejaculate of males of infertile couples and the likelihood of pregnancy in partners.
The study group comprised 30 men aged between 26 and 43 years (mean 33 +/- 4.8 years) with idiopathic infertility. All patients received Speroton one sachet once daily during meals for 3 months. The comparison group consisted of 29 men of fertile age having 1 to 3 healthy children. In infertile men, standard semen parameters including the ejaculate volume, sperm concentration, total count and proportion of abnormal forms were within the normal range. Markers of oxidative damage to ejaculate macromolecules were determined using standard diagnostic testing systems.
The patients with idiopathic infertility were found to have statistically significant changes in the degree of chemical modification of ejaculate biopolymers. The level of lipid hydroperoxides in infertile men was significantly higher than in fertile participants. Taking Speroton resulted in the decrease of lipid hydroperoxides to the level that did not differ from that in the control group. Using Speroton was also accompanied by a decrease in the level of the oxidative damage DNA biomarker 8-oxodGu and a tendency toward normalization of the carbonyl modification of the ejaculate proteins. Five married couples in the treatment group reported achieving pregnancy.
Taking Speroton was associated with the normalization of the balance of pro- and antioxidant processes in the ejaculate, as indicated by a decrease in the oxidative destruction of sperm biopolymers. The revealed molecular mechanism of the drug action is the basis for restoring the fertilizing ability and increasing the likelihood of pregnancy. The treatment effectiveness was 16.7%. Speroton is a promising drug that improves the functional sperm characteristics and contributes to achieving pregnancy in couples with a male infertility factor.
研究施倍特复合物对不育夫妇男性精液中自由基稳态的影响以及伴侣怀孕的可能性。
研究组包括30名年龄在26至43岁（平均33±4.8岁）的特发性不育男性。所有患者每天用餐时服用1袋施倍特，持续3个月。对照组由29名有1至3个健康孩子的育龄男性组成。不育男性的标准精液参数，包括精液量、精子浓度、总数和异常形态比例均在正常范围内。使用标准诊断测试系统测定精液大分子氧化损伤的标志物。
发现特发性不育患者精液生物聚合物的化学修饰程度有统计学显著变化。不育男性的脂质过氧化氢水平显著高于生育男性。服用施倍特后，脂质过氧化氢水平降至与对照组无差异的水平。使用施倍特还伴随着氧化损伤DNA生物标志物8-氧代脱氧鸟苷水平的降低以及精液蛋白羰基修饰趋于正常化的趋势。治疗组中有五对已婚夫妇报告怀孕。
服用施倍特与精液中促氧化和抗氧化过程平衡的正常化有关，表现为精子生物聚合物氧化破坏的减少。所揭示的药物作用分子机制是恢复受精能力和增加怀孕可能性的基础。治疗有效率为16.7%。施倍特是一种有前景的药物，可改善精子功能特性并有助于有男性不育因素的夫妇怀孕。
